Elemental impurities in pharmaceutical products are not a theoretical concern—they are a patient safety issue with well-documented toxicological consequences. The United States Pharmacopeia (USP) classifies arsenic (As), cadmium (Cd), lead (Pb), and mercury (Hg) as Class 1 elements, often referred to as the “Big Four.” These four elements are considered the highest-priority impurities because of their toxicity, prevalence in nature, and potential to contaminate raw materials, excipients, and finished drug products.

Under USP <232> Elemental Impurities—Limits and USP <233> Elemental Impurities—Procedures, testing for these elements is mandatory for all drug products—regardless of route of administration. This post provides a detailed look at each element, their toxicity profiles, the regulatory limits that govern them, and the analytical strategies used to detect and quantify them.

Why the “Big Four” Are Singled Out

USP <232> organizes elemental impurities into three classes. Class 1 contains elements that are toxic to humans and have limited or no use in pharmaceutical manufacturing. Arsenic, cadmium, lead, and mercury fall squarely into this category. Unlike Class 2 elements (which are route-dependent and tied to specific manufacturing processes) or Class 3 elements (which have relatively low toxicity), Class 1 elements must be evaluated in every risk assessment for every drug product.

The rationale is straightforward: these elements are ubiquitous in the environment and can enter the pharmaceutical supply chain through mined mineral excipients, water sources, catalysts, and container-closure systems. Even trace-level contamination can have serious health consequences with chronic exposure.

Understanding the Regulatory Framework: USP <232> and <233>

USP <232> and <233> replaced the legacy USP <231> Heavy Metals Test on 1 January 2018, marking a fundamental shift from a semi-quantitative, colour-comparison wet-chemistry method to modern, element-specific instrumental analysis.

USP <232>: Defining the Limits

USP <232> establishes Permitted Daily Exposure (PDE) limits for 24 elemental impurities, expressed in micrograms per day (µg/day). Limits vary by route of administration—oral, parenteral, and inhalational—reflecting the different bioavailability and toxicity risks associated with each exposure pathway.

For the Class 1 “Big Four,” the PDE limits are as follows:

Table 1: USP <232> Permitted Daily Exposure (PDE) limits for Class 1 elemental impurities by route of administration.

Note that arsenic limits are based on the inorganic form (the most toxic speciation), while mercury limits are based on inorganic Hg²⁺. For practical purposes, total arsenic and total mercury measurements are accepted, operating under the conservative assumption that all detected arsenic or mercury is in its most toxic form.

For a deeper technical discussion of how these limits were derived, read our General Observations Regarding USP 232.

USP <233>: Analytical Procedures and Validation

USP <233> prescribes two instrumental procedures for quantifying elemental impurities:

•   Procedure 1: ICP‑OES (Inductively Coupled Plasma Optical Emission Spectroscopy) – suitable for elements present at higher concentrations.

•   Procedure 2: ICP‑MS (Inductively Coupled Plasma Mass Spectrometry) – the preferred technique for the Big Four due to its superior sensitivity, capable of detecting impurities at parts-per-billion (ppb) and sub-ppb levels.

USP <233> also defines rigorous validation requirements, including method suitability, spike recovery (between 70–150%), and detection-limit verification. These requirements ensure that any analytical method used to assess compliance with USP <232> is fit for purpose.

Learn more about how elemental impurities testing is carried out in pharmaceutical quality control laboratories.

Toxicity Profiles and Analytical Considerations for Each Element

Arsenic (As)

Arsenic is classified by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. Chronic exposure is associated with skin, lung, and bladder cancers, as well as cardiovascular disease and neurological impairment. Inorganic arsenic compounds (arsenite and arsenate) are significantly more toxic than organic arsenic species, which is why USP <232> sets its PDE limits based on the inorganic form.

Analytical challenges: In ICP‑MS, arsenic (m/z 75) suffers from a well-known polyatomic interference from ⁴⁰Ar³⁵Cl⁺, which is particularly problematic in samples containing hydrochloric acid or chloride salts. This interference can be resolved using collision/reaction cell (CRC) technology in helium kinetic energy discrimination (KED) mode, or by avoiding HCl in sample preparation altogether. For guidance on selecting the right acid matrix, see our acid matrix selection guide for ICP.

Cadmium (Cd)

Cadmium is an IARC Group 1 carcinogen primarily targeting the kidneys and skeletal system. It has an exceptionally long biological half-life in the human body (10–30 years), meaning even low-level chronic exposure leads to bioaccumulation and progressive organ damage. Cadmium exposure through the inhalation route is particularly hazardous, reflected in its lower PDE limit of 1.5 µg/day for inhalation products compared to 2.5 µg/day for oral and parenteral routes.

Analytical challenges: Cadmium is generally straightforward to measure by ICP‑MS using isotopes ¹¹¹Cd or ¹¹³Cd. Potential isobaric interferences from tin (Sn) and indium (In) oxides are rare in pharmaceutical matrices but should be monitored during method development. Cadmium’s relative ease of measurement makes it an excellent candidate for multi-element screening runs.

Lead (Pb)

Lead is a systemic toxicant with no known safe threshold of exposure. It affects the nervous system, kidneys, and haematopoietic system, with children being particularly vulnerable. USP <232> sets a uniform PDE of 5.0 µg/day across all three routes of administration, underscoring its universal concern.

Analytical challenges: Lead is well-suited to ICP‑MS measurement and relatively free from significant spectral interferences. Its four stable isotopes (²⁰⁴Pb, ²⁰⁶Pb, ²⁰⁷Pb, ²⁰⁸Pb) provide flexibility in isotope selection. However, lead can exhibit memory effects in sample introduction systems due to its tendency to adsorb onto glass and plastic surfaces. Thorough washout protocols between samples are essential for accurate quantification.

Mercury (Hg)

Mercury toxicity varies dramatically with its chemical form. Methylmercury is the most toxic species and is primarily associated with dietary exposure (fish consumption) rather than pharmaceutical contamination. USP <232> bases its limits on inorganic mercury (Hg²⁺), which is the form more likely to be present in pharmaceutical materials. The oral PDE is relatively higher at 15 µg/day, while parenteral and inhalational routes are set at 1.5 µg/day due to increased bioavailability.

Analytical challenges: Mercury is notoriously difficult to handle in trace analysis. Its volatility leads to losses during sample preparation (especially open-vessel digestion), and it adsorbs readily onto container walls. Gold (Au) stabilisation at 200–500 ppb in calibration standards and rinse solutions is a common best practice to prevent mercury carryover and memory effects. Separate single-element mercury standards are often recommended over inclusion in multi-element blends for this reason. For more on standard stability, see our technical paper on USP 232 and ICH Q3D element stability in ICP standards.

Analytical Strategy for Accurate Big Four Quantification

Meeting USP <232>/<233> requirements for the Class 1 elements demands a robust analytical workflow. Here are the key considerations:

Sample Preparation

•   Closed-vessel microwave-assisted acid digestion is preferred to minimise volatilisation losses (critical for As and Hg).

•   Use high-purity nitric acid (HNO₃) as the primary digestion acid. Avoid hydrochloric acid (HCl) where possible to reduce the ⁴⁰Ar³⁵Cl⁺ interference on arsenic.

•   Add gold (Au) at 200–500 ppb to all solutions containing mercury to prevent adsorption losses.

•   For detailed element-by-element preparation guidance, consult our sample preparation guides.

Calibration and Standards

•   Use certified reference materials (CRMs) that are NIST-traceable with documented uncertainty values.

•   Inorganic Ventures offers ready-made USP <232> Class 1 Oral Elemental Impurities standards, Parenteral standards, and Drug Substance & Excipients standards formulated to match USP <232> target concentrations.

•   Matrix-match calibration standards to your sample digest to minimise matrix effects. See our guide on how to ensure accurate elemental impurities testing results.

The J Value: Converting Results to PDE Units

Analytical results from ICP‑MS are typically reported in concentration units (µg/L or ppb), but USP <232> limits are expressed in µg/day. Converting between the two requires knowledge of the maximum daily dose of the drug product. The J value is the calculation factor used to bridge this gap, and understanding it is essential for determining pass/fail against USP <232> limits.

For a full explanation of this conversion, read our post on elemental analysis of pharmaceutical samples using the J value.

Incorporating the Big Four into Your Risk Assessment

USP <232> encourages a science- and risk-based approach to elemental impurities control. For the Big Four, this means:

1. Identify potential sources: Review raw material specifications, excipient certificates of analysis, water quality data, manufacturing equipment materials, and container-closure compatibility.

2. Evaluate likelihood of contamination: Class 1 elements are environmentally ubiquitous, so the question is not whether they are present, but at what levels.

3. Test and verify: Confirmatory testing with ICP‑MS is the gold standard. Periodic monitoring of incoming materials establishes baseline data and catches supply-chain shifts early.

4. Document everything: Regulatory inspections expect a documented risk assessment with supporting analytical data demonstrating that finished products meet PDE limits.

For a complete look at regulatory compliance standards and products, visit our compliance resource centre.

Frequently Asked Questions

What are the Big Four elemental impurities in USP <232>?

The Big Four are arsenic (As), cadmium (Cd), lead (Pb), and mercury (Hg). They are classified as Class 1 elemental impurities under USP <232> because of their high toxicity and the fact that they have limited or no therapeutic benefit. Testing for these four elements is mandatory for all pharmaceutical drug products, regardless of the route of administration.

What is the difference between USP <232> and USP <233>?

USP <232> defines the permissible limits (Permitted Daily Exposure values) for 24 elemental impurities in pharmaceutical products. USP <233> specifies the analytical procedures (ICP‑OES and ICP‑MS) and validation requirements for measuring those impurities. In short, <232> tells you how much is allowed; <233> tells you how to measure it.

Why are Class 1 impurities tested for all drug products?

Because arsenic, cadmium, lead, and mercury are naturally occurring environmental contaminants that can enter pharmaceutical products through multiple pathways—raw materials, water, excipients, and processing equipment. Their severe toxicity at even trace levels, combined with their ubiquity, means the risk of contamination can never be assumed to be zero.

How are elemental impurities tested in pharmaceutical products?

The standard approach involves acid digestion of the sample (typically closed-vessel microwave digestion with nitric acid), followed by analysis using ICP‑MS (preferred for the Big Four due to its sensitivity at ppb levels) or ICP‑OES. The method must be validated per USP <233> requirements, including spike recovery, detection limits, and specificity.

What are the PDE limits for arsenic, cadmium, lead, and mercury?

PDE limits vary by route of administration. Arsenic: 1.5 µg/day across all routes. Cadmium: 2.5 µg/day oral and parenteral, 1.5 µg/day inhalation. Lead: 5.0 µg/day across all routes. Mercury: 15 µg/day oral, 1.5 µg/day parenteral and inhalation. These reflect chronic exposure limits intended to protect patient safety over a lifetime of use.

Ensuring Compliance and Patient Safety

The USP “Big Four” elemental impurities—arsenic, cadmium, lead, and mercury—represent the most critical analytical targets in pharmaceutical elemental impurities testing. Their mandatory classification under USP <232>, combined with the rigorous analytical demands of USP <233>, means that pharmaceutical manufacturers and testing laboratories need reliable standards, proven methods, and a thorough understanding of the unique challenges each element presents.

Inorganic Ventures provides a complete portfolio of NIST-traceable certified reference materials specifically designed for USP <232>/<233> compliance testing, including Class 1 Oral, Parenteral, and Drug Substance & Excipients standards. Our technical support team is available to help you select the right standards and optimise your analytical methods for accurate, compliant results.

Need certified reference materials for USP <232> testing? Browse our full range of USP compliance standards →